Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients... Show more
A.I.dvisor tells us that NBTX and CGEN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and CGEN's prices will move in lockstep.
| Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
|---|---|---|---|---|
| NBTX | 100% | +7.00% | ||
| CGEN - NBTX | 32% Poorly correlated | -0.93% | ||
| ASMB - NBTX | 31% Poorly correlated | -3.45% | ||
| CLLS - NBTX | 31% Poorly correlated | -2.17% | ||
| NTLA - NBTX | 30% Poorly correlated | -1.60% | ||
| XBIO - NBTX | 30% Poorly correlated | -1.00% | ||
More | ||||
Industry Biotechnology
The Moving Average Convergence Divergence (MACD) for NBTX turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NBTX's RSI Oscillator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where NBTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NBTX as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +22.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NBTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for NBTX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-44.525) is normal, around the industry mean (2.988). P/E Ratio (-26.780) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. NBTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.